LBRX

LB Pharmaceuticals Inc Common Stock

Investor Moves

InvestorPortfolio ValuePortfolio ChangePosition ChangeAvg Buy PriceCurrent Price
Ken GriffinCitadel Advisors
$-9.1M
ExitQ1 2026
$9.1M
--
$27.80
Jefferies GroupInvestor
$-277.0K
ExitQ1 2026
$277k
--
$27.80
Ken GriffinCitadel Advisors
$9.1M407.7k shares
ExitQ4 2025
$8.5M
$22.26
$27.80
Ken GriffinCitadel Advisors
$9.1M407.7k shares
AddQ4 2025
$558k
$22.26
$27.80
Jefferies GroupInvestor
$277k12.4k shares
ExitQ4 2025
$207k
$22.26
$27.80
Jefferies GroupInvestor
$277k12.4k shares
AddQ4 2025
$70k
$22.26
$27.80

News

globenewswire.comLB Pharmaceuticals to Participate in Upcoming June Investor Eventsglobenewswire.comMay 28zacks.comAll You Need to Know About LB Pharmaceuticals Inc (LBRX) Rating Upgrade to Buyzacks.comMay 26globenewswire.comLB Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Updateglobenewswire.comMay 12globenewswire.comLB Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Updateglobenewswire.comMay 12globenewswire.comLB Pharmaceuticals Announces Publication in JAMA Psychiatry of Results from Phase 2 NOVA-1 Trial of LB-102 in Schizophreniaglobenewswire.comApr 22